Such compounds may be highly efficacious without dose-limiting adverse effects witnessed in clinical trials where pan-BET bromodomain inhibitors have been used [reviewed in (39)], especially in diseases like T1D where patient populations are primarily pediatric. Here, DNER is linked to type 1 diabetes mellitus.